Is Teva Pharma's Restructuring Plan Actually 'More Reasonable'? [Investor's Business Daily]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Investors Business Daily
Technology Related news 12:32 PM ET Regeneron should benefit after Novartis and Roche presented data for competitors to blockbuster eye drug Eylea. IBD Rating Upgrades: Momenta Pharmaceuticals Shows Improved Technical Strength Biotech Investors Flee In Droves As Market Correction Rocks The Group Regeneron Dips In Sympathy With Biotechs Despite Quarterly Beat Teva Beats Quarterly Views But Dives On Weak 2018 Guidance GlaxoSmithKline Slips On 2018 Guidance As Generic Advair Looms Teva Pharmaceutical Reaches 80-Plus Relative Strength Rating Benchmark Gilead Beats Quarterly Views, But Topples On Soft 2018 Guidance These Biotech Stocks Each Dived More Than 20% — Is The Sell-Off Overdone? Teva Pharmaceutical ( TEVA ) jumped Monday after grabbing an upgrade and a price target boost on its 2018 restructuring plan which looks "more reasonable," one analyst said. X Credit Suisse analyst Vamil Divan upgraded Teva to an outperform rating from n
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Indian shares set to open higher tracking Asian peers [Reuters]Reuters
- Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India [Yahoo! Finance]Yahoo! Finance
- Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaGlobeNewswire
- Global Freeze Drying Market Size To Exceed USD 10.9 Billion By 2033 | CAGR of 8.55% [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics GAAP EPS of -$0.79 [Seeking Alpha]Seeking Alpha
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 3/27/24 - Form 6-K
- 3/22/24 - Form 6-K
- 3/22/24 - Form 6-K
- RDY's page on the SEC website